Investment accounts
Adult accounts
Child accounts
Choosing Fidelity
Choosing Fidelity
Why invest with us Current offers Fees and charges Open an account Transfer investments
Financial advice & support
Fidelity’s Services
Fidelity’s Services
Financial advice Retirement Wealth Management Investor Centre (London) Bereavement
Guides
Guidance and tools
Shares
Share dealing
Choose your shares
Tools and information
Tools and information
Share prices and markets Chart and compare shares Stock market news Shareholder perks Stock plan guidance
Pensions & retirement
Pensions, tax & tools
Saving for retirement
Approaching / In retirement
Approaching / In retirement
Speak to a specialist Creating a retirement plan Taking tax-free cash Pension drawdown Annuities Investing in retirement Investment Pathways
Ilika reports technical progress across battery programmes
(Sharecast News) - Ilika reported continued technical progress across its solid-state battery programmes on Thursday, and confirmed it remained on schedule to release its next-generation Goliath prototypes by year-end, although first-half revenue and EBITDA reflected increased investment in development and testing. In an update for the six months ended 31 October, the company said revenue is expected to be £0.6m, down from £1m a year earlier, mainly due to the phasing of income from the government-funded Drive35 Primed programme, which began in August and would accelerate in the second half.
EBITDA loss, excluding share-based payments, widened to £3.2m from £1.9m as costs increased ahead of the release of 10Ah Goliath prototypes.
Cash and equivalents at the end of the period were £6.9m, compared with £10.1m a year earlier.
Half-year results would be published on 22 January.
Ilika highlighted further milestones in its Stereax micro-battery line, which serves active implantable medical devices and wireless sensors.
In August, Cirtec Medical, the company's licensing and manufacturing partner, completed process qualification of the Stereax M300 line at its Massachusetts facility.
That followed equipment commissioning in January and marked the final technical step before production.
Ilika said the qualified line incorporated advanced layer deposition, alignment and patterning systems required for medical-grade micro-batteries.
Subject to "any last-minute delays due to international logistics over the US-UK festive period," initial M300 deliveries to lead customers were targeted for the fourth quarter of 2025.
The company also advanced its Goliath programme, which develops large-format solid-state batteries for electric vehicles and consumer applications.
It said its 2Ah P1 prototypes were validated by OEM and Tier 1 partners early in the period, and in July Ilika secured £1.25m in grant funding under a £3m Advanced Propulsion Centre programme to support production of the first automotive A-Samples.
Jaguar Land Rover and professor Paul Shearing of Oxford University joined the project as strategic advisors in September.
Ilika said its automated assembly line for the Goliath pilot plant was fully commissioned last month, improving yields and enabling the higher volumes required for customer testing.
The company remained on track to begin releasing 10Ah prototypes to customers in December, with 50Ah cells to follow based on customer feedback and demand.
At 1506 GMT, shares in Ilika were up 2.33% at 44p.
Reporting by Josh White for Sharecast.com.
Share this article
Related Sharecast Articles
Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.
Award-winning online share dealing
Search, compare and select from thousands of shares.
Expert insights into investing your money
Our team of experts explore the world of share dealing.
Policies and important information
Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme
Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document which contains important information about the fund.
This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.